pleasant new year surpris itacitinib
fail phase trial steroid-nav acut gvhd
itacitinib steroid acut gvhd meet primari endpoint improv
overal respons vs placebo steroid follow posit phase data approv
ruxolitinib steroid-refractori agvhd neg result
somewhat surpris good way begin year today failur
highlight concern weaker pipelin compar larger-cap biotech peer
speak investor late last year got sens trial like succeed
given result remov credit itacitinib mode model s-
 agvhd approxim po forecast peak across
us address european market well visibl alpha consensu peak
could result greater declin share overal
think higher bar demonstr efficaci gvhd challeng given result
trial reduc tp reiter neutral rate
initi clinic data demonstr clinic differ trial arm specif
orr activ arm day primari endpoint vs placebo vs
respect cite higher anticip respons rate placebo
corticosteroid arm like reason neg result follow-up convers
compani compani state disappoint result necessarili read-through
trial howev given complex diseas combin neg
result low confid drug abil deliv posit result
steroid-nav chronic gvhd still includ credit itacitinib
chronic set state on-going power detect
clinic meaning result therefor trial like upsiz await posit
clinic data addit clariti remain commerci opportun assign
credit model
model chang remov itacitinib revenu model ep
unchang forecast ep
risk dcf-base tp rate commerci market price regulatori
valuat metric
number share
 close
legal entiti disclosur statu non-u analyst us disclosur credit suiss seek busi
compani cover research report result investor awar firm may conflict interest could
affect object report investor consid report singl factor make invest decis
profit tax
associ
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
price
incyt corp biopharmaceut compani engag
discoveri develop commerci proprietari therapeut
oncolog hematolog dermatolog
blue sky upsid case valuat base fda
approv pemigatinib cholangiocarcinoma within next
month also assum better expect jakafi revenu
grey sky downsid valuat assum fda
approv pemigatinib grey sky also assum neg data readout
pemigatinib urotheli cancer also assum jakafi revenu
lower expect
 close
previous estim itacitinib would contribut risk-
adjust revenu worth model despit modest opportun
rel jakafi itacitinib would provid degre revenu diversif
continu believ jakafi gener priced-in stock point believ
upsid would driven pipelin remain posit topic ruxolitinib
atop dermat vitiligo pipelin asset capmatinib pemigatinib parsaclisib
earlier stage repres modest commerci opportun look next phase
readout topic ruxolitinib ad nda approv pemigatinib
one-year price target deriv base-cas dcf analysi use
discount rate fulli dilut share believ discount rate
reflect risk futur cash flow year experi commerci
jakafi view best-in-class product current minim near-term
competit threat assum lower wacc confid abil
market commerci jakafi
incyt corpor million priorcurrentchangepriorcurrentchangejakafi ruxolitinib sale ruxolitinib royalti revenu loss incom cs dilut cs charl martineau pm univers toronto januari
compani mention price
evan seigerman certifi view express report accur reflect person view subject compani
secur part compens directli indirectli relat specif recommend view express
report
